Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy - PubMed
4 hours ago
- #metabolic profiling
- #TNBC
- #chemo-immunotherapy
- Study focuses on triple-negative breast cancer (TNBC) treatment challenges.
- Uses single-cell RNA sequencing and metabolic analysis to study TNBC.
- Reveals metabolic heterogeneity in TNBC at gene, pathway, and flux levels.
- Identifies cell-type-specific metabolic traits linked to treatment response.
- Finds dynamic collaboration between tumor and myeloid cells via glucose and lactate.
- MCT1 inhibitors disrupt tumor-myeloid interaction, boosting anti-PD-1 and ADC efficacy.
- Positions MCT1 as a promising therapeutic target in TNBC.